Syndax Pharmaceuticals Inc [NASDAQ: SNDX] price surged by 11.56 percent to reach at $1.59.
A sum of 7199302 shares traded at recent session while its average daily volume was at 2.78M shares. Syndax Pharmaceuticals Inc shares reached a high of $15.795 and dropped to a low of $13.15 until finishing in the latest session at $15.35.
The one-year SNDX stock forecast points to a potential upside of 60.49. The average equity rating for SNDX stock is currently 1.07, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Syndax Pharmaceuticals Inc [SNDX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNDX shares is $38.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNDX stock is a recommendation set at 1.07. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Syndax Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 16, 2025. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on September 10, 2025, representing the official price target for Syndax Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $34, while Guggenheim analysts kept a Buy rating on SNDX stock. On August 05, 2025, analysts increased their price target for SNDX shares from 43 to 56.
The Price to Book ratio for the last quarter was 11.56, with the Price to Cash per share for the same quarter was set at 5.06.
SNDX Stock Performance Analysis:
Syndax Pharmaceuticals Inc [SNDX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.62. With this latest performance, SNDX shares dropped by -6.40% in over the last four-week period, additionally plugging by 44.27% over the last 6 months – not to mention a rise of 16.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNDX stock in for the last two-week period is set at 56.12, with the RSI for the last a single of trading hit 1.17, and the three-weeks RSI is set at 1.01 for Syndax Pharmaceuticals Inc [SNDX]. The present Moving Average for the last 50 days of trading for this stock 15.32, while it was recorded at 13.88 for the last single week of trading, and 12.96 for the last 200 days.
Insight into Syndax Pharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Syndax Pharmaceuticals Inc [SNDX] shares currently have an operating margin of -274.90% and a Gross Margin at 95.43%. Syndax Pharmaceuticals Inc’s Net Margin is presently recorded at -279.31%.
Syndax Pharmaceuticals Inc (SNDX) Capital Structure & Debt Analysis
According to recent financial data for Syndax Pharmaceuticals Inc. ( SNDX), the Return on Equity (ROE) stands at -129.32%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -63.74%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Syndax Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -71.20%, showcasing its effectiveness in deploying capital for earnings.
Syndax Pharmaceuticals Inc (SNDX) Efficiency & Liquidity Metrics
Based on Syndax Pharmaceuticals Inc’s (SNDX) latest financial statements, the Debt-to-Equity Ratio is 2.99%, indicating its reliance on debt financing relative to shareholder equity.
Syndax Pharmaceuticals Inc (SNDX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Syndax Pharmaceuticals Inc. (SNDX) effectively leverages its workforce, generating an average of -$1154000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.64% and a Quick Ratio of 4.42%, indicating strong ability to cover short-term liabilities.
SNDX Stock EPS
With the latest financial reports released by the company, Syndax Pharmaceuticals Inc posted -1.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.87. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNDX.
Syndax Pharmaceuticals Inc [SNDX] Institutonal Ownership Details
There are presently around $121.04%, or 122.62%% of SNDX stock, in the hands of institutional investors. The top three institutional holders of SNDX stocks are: BLACKROCK INC. with ownership of 7.91 million shares, which is approximately 9.2721%. WELLINGTON MANAGEMENT GROUP LLP, holding 7.34 million shares of the stock with an approximate value of $$150.67 million in SNDX stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $$117.47 million in SNDX stock with ownership which is approximately 6.7101%.
